Trial Profile
An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs SAR 422459 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors Oxford BioMedica; Sanofi
- 01 Jun 2023 Planned End Date changed from 1 Aug 2034 to 29 Aug 2033.
- 01 Jun 2023 Planned primary completion date changed from 1 Aug 2034 to 29 Aug 2033.
- 10 Aug 2020 Planned End Date changed from 1 Aug 2033 to 1 Aug 2034.